Please login to the form below

Not currently logged in
Email:
Password:

Nexavar

This page shows the latest Nexavar news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

s marketed cancer drug Nexavar (sorafenib), sending shares in both companies into a slump. ... Nexavar – an oral multikinase inhibitor – is a standard first-line therapy for HCC.

Latest news

  • Liver cancer failure dents Opdivo potential by $1bn, says analyst Liver cancer failure dents Opdivo potential by $1bn, says analyst

    As it turned out, Opdivo failed to improve overall survival (OS) when compared to Bayer’s targeted cancer drug Nexavar (sorafenib) in the CheckMate-459 trial involving patients with previously-untreated ... There was a trend towards an improvement in

  • Lilly scores FDA okay for Cyramza in liver cancer Lilly scores FDA okay for Cyramza in liver cancer

    Approved as second line treatment after Bayer’s Nexavar. Eli Lilly has added a fifth indication for its cancer drug Cyramza, getting an FDA approval for hepatocellular carcinoma (HCC) that expresses ... The FDA approval is for Cyramza (ramucirumab) –

  • AVEO warns EU approval of Fotivda could be at risk AVEO warns EU approval of Fotivda could be at risk

    TIVO-1 showed that Fotivda was superior to rival drug Nexavar (sorafenib) from Bayer in extending progression-free survival (PFS) in this patient group, and that was enough evidence for the ... TIVO-3 backed up the PFS finding of TIVO-1 with a 44%

  • More good news, and some bad, for Merck’s Keytruda More good news, and some bad, for Merck’s Keytruda

    failed to show an increase in survival compared to placebo and supportive care in patients previously treated with Bayer’s targeted therapy Nexavar (sorafenib). ... to move its drug into first-line use based on the CheckMate-459 study which pits Opdivo

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Meanwhile, other orally-active drugs that target VEGF – including Bayer’s Nexavar (sorafenib), Novartis’ Votrient (pazopanib), and Sanofi’s Caprelsa (vandetanib) – have been developed for a range of other solid tumours

More from news
Approximately 8 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    In its phase 3 trial it was compared with a single rival targeted therapy, Nexavar (sorafenib). ... A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics